FDA Inspection 1219023 — Aurobindo Pharma Limited

Aurobindo Pharma Limited — FEI 3004021263

The FDA completed an inspection of Aurobindo Pharma Limited on September 29, 2023 in Sangareddy. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 1 citation was issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
September 29, 2023
Fiscal Year
2023
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Sangareddy (India)

Citations

IDCFRDescription
358521 CFR 211.110(a)Control procedures to monitor and validate performance